#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 25 '26)

 

Ann Intern Med

1. LIM SY, Lee J, Chang E, Kwon JS, et al
   Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-04883.
   PubMed         Abstract available
   
   
2. QASEEM A, Obley AJ, Yost J, Abraham GM, et al
   Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03766.
   PubMed         Abstract available
   
   
3. SOMMER I, Dobrescu A, Gadinger A, Sharifan A, et al
   Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03691.
   PubMed         Abstract available
   
   

   
   Biochemistry

4. MEDEIROS-SILVA J, Zhang Y, Hong M
   Phosphatidylinositol Interactions with the SARS-CoV-2 Envelope Protein Investigated by Lipid (13)C Labeling and Solid-State NMR.
   Biochemistry. 2026;65:1178-1191.
   PubMed         Abstract available
   
   

   
   J Infect

5. COX SN, Bennett JC, Casto AM, Hoffman KL, et al
   INFLUENZA HOUSEHOLD TRANSMISSION AND GENOMIC DIVERSITY IN THE UNITED STATES: A PROSPECTIVE COHORT STUDY, 2022-2024.
   J Infect. 2026 Apr 20:106748. doi: 10.1016/j.jinf.2026.106748.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG R, Jian X, Zhang Y, Sun Y, et al
   The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.
   J Virol. 2026 Apr 21:e0000626. doi: 10.1128/jvi.00006.
   PubMed         Abstract available
   
   
7. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   PubMed         Abstract available
   
   
8. KONG W, Zhang J, Song Y, Song J, et al
   Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.
   J Virol. 2026 Mar 30:e0027026. doi: 10.1128/jvi.00270.
   PubMed         Abstract available
   
   
9. XIU R, Wang Y, Cai W, Wang Q, et al
   Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.
   J Virol. 2026 Mar 30:e0007626. doi: 10.1128/jvi.00076.
   PubMed         Abstract available
   
   
10. BRENNAN JW, Wang G, Connor S, Wang X, et al
    A respiratory syncytial virus trailer sequence modulates viral replication and the generation and propagation kinetics of copy-back defective viral genomes.
    J Virol. 2026;100:e0018426.
    PubMed         Abstract available
    
    
11. ADAM A, Wu W, Jones MC, Hao H, et al
    Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through gammadelta T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells.
    J Virol. 2026 Mar 18:e0165825. doi: 10.1128/jvi.01658.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

12. BELL JM, Barbre K, Meng L, Lape-Newman B, et al
    Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2026;75:195-201.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Pediatrics

14. SEGEV N, Wilson E, Moehlman M, Corathers SD, et al
    Unmasking Adrenal Insufficiency: Adrenal Crisis Triggered by Influenza-Associated Encephalitis.
    Pediatrics. 2026 Apr 22:e2025072983. doi: 10.1542/peds.2025-072983.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

15. LI Y, Nielsen BF, Levin SA, Te Velthuis AJW, et al
    Spatio-temporal modelling of in vitro influenza A virus infection: The impact of defective interfering particles on the type I interferon response.
    PLoS Comput Biol. 2026;22:e1014198.
    PubMed         Abstract available
    
    
16. WHITE LA, Leon TM
    Forecastability of infectious disease time series: are some seasons and pathogens intrinsically more difficult to forecast?
    PLoS Comput Biol. 2026;22:e1014175.
    PubMed         Abstract available
    
    

    
    PLoS One

17. ORTEGA-MARTIN E, Alvarez-Galvez J
    Understanding quality-of-life patterns in long COVID: How Symptoms and socioeconomic conditions shape patient wellbeing.
    PLoS One. 2026;21:e0347743.
    PubMed         Abstract available
    
    
18. CHAVES SS, Castells VB, Mira-Iglesias A, Puig-Barbera J, et al
    Rhinovirus/enterovirus contribution to respiratory-associated hospitalizations in adults during respiratory seasons in Spain: A 6-year prospective study.
    PLoS One. 2026;21:e0347659.
    PubMed         Abstract available
    
    
19. LEE J, Bajiya VP, Jung E
    Vaccination scenario-based study on seasonal influenza in Republic of Korea.
    PLoS One. 2026;21:e0322686.
    PubMed         Abstract available
    
    
20. PIRZADA P, Wilde A, Doherty GH, Harris-Birtill D, et al
    Understanding older adults' perception, acceptance, and adoption of smart home technologies.
    PLoS One. 2026;21:e0345563.
    PubMed         Abstract available
    
    
21. FANG Z, Xu H, Mu Y
    Risk-taking responses to crash experience: Evidence from China.
    PLoS One. 2026;21:e0347543.
    PubMed         Abstract available
    
    
22. GARZA J, Sebastian R, Cover B, Sanchez A, et al
    Nicotine dependence among critically ill COVID-19 patients: A population-based cohort study.
    PLoS One. 2026;21:e0308776.
    PubMed         Abstract available
    
    
23. MCDONALD C, Grajales AG, Yahia NA, Fisman D, et al
    Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023.
    PLoS One. 2026;21:e0344690.
    PubMed         Abstract available
    
    
24. LOVATO N, Appleton SL, Reynolds AC, Gill TK, et al
    Relationships between pre-pandemic mental health, sociodemographic factors and health behaviours in older adults during the acute onset of COVID-19 in Australia: A descriptive analysis.
    PLoS One. 2026;21:e0346787.
    PubMed         Abstract available
    
    
25. AUDUREAU E, Jean C, Layese R, Neuraz A, et al
    Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.
    PLoS One. 2026;21:e0346679.
    PubMed         Abstract available
    
    
26. IPEKCI AM, Hodel EM, Filsinger M, Wegmuller S, et al
    Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey.
    PLoS One. 2026;21:e0346420.
    PubMed         Abstract available
    
    
27. YANG Z, Imouza A, Puelma Touzel M, Amadoro C, et al
    Regional and temporal patterns of partisan polarization during the COVID-19 pandemic in the United States and Canada.
    PLoS One. 2026;21:e0347327.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. SANDERS CG, Liu M, Fusco JA, Ohl EM, et al
    Efficient replication of influenza D virus in the human airway underscores zoonotic potential.
    Proc Natl Acad Sci U S A. 2026;123:e2530325123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. ROBERTSON AH, Wolf AS, Fossum E, Solum G, et al
    Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
    Vaccine. 2026;80:128511.
    PubMed         Abstract available
    
    
30. DLOUHY P, Petras M, Lesna IK, Macalik R, et al
    Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.
    Vaccine. 2026;80:128535.
    PubMed         Abstract available
    
    
31. VAN DE BURGWAL LHM, Pronker ES, Herz J
    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment.
    Vaccine. 2026;80:128525.
    PubMed         Abstract available
    
    
32. WU D, Liu K
    Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.
    Vaccine. 2026;80:128536.
    PubMed         Abstract available
    
    
33. MAEDA H, Saito N, Igarashi A, Ishida M, et al
    Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.
    Vaccine. 2026;80:128544.
    PubMed         Abstract available
    
    
34. MORO PL, Romanson B, Marquez P, Zhang B, et al
    Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.
    Vaccine. 2026;80:128547.
    PubMed         Abstract available
    
    
35. QUINTANAR-SOLARES M, Fleming JA, Musau W, Mulati F, et al
    RSV ready? Exploring feasibility and acceptability of RSV immunization options in low- and middle-income countries.
    Vaccine. 2026;80:128550.
    PubMed         Abstract available
    
    
36. KITANO T, Hashimoto E, Sado T, Yoshida S, et al
    Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: A retrospective cohort study.
    Vaccine. 2026;80:128566.
    PubMed         Abstract available
    
    
37. ZHANG L, Lin T, Wang M, Ma X, et al
    Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial.
    Vaccine. 2026;82:128588.
    PubMed         Abstract available
    
    
38. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.
    Vaccine. 2026;82:128582.
    PubMed         Abstract available
    
    
39. RICE E, Cheng AC, Britton PN, Carr J, et al
    Influenza epidemiology, treatment and prevention in Australian children: Trends from 6 years of PAEDS-FluCAN influenza surveillance (2019-2024).
    Vaccine. 2026;82:128592.
    PubMed         Abstract available

The ‘Spanish’ #influenza #pandemic: new #evidence for influenza #outbreaks in #England and #France prior to 1918

 

Abstract

The Spanish influenza pandemic of 1918 caused well over fifty million deaths. The epicentre undoubtedly was China, where gene mixing of different virus strains occurred amongst aquatic, migrant birds. But where and when did the virus first infect (or spill over to) a human being? We take, as our starting point, a paper demonstrating that an infection causing the same symptoms as the influenza virus was widespread in New York during the winter of 1917–1918. The authors of that paper went on to suggest that the virus had probably reached North America from Europe, in the context of troop movement during World War I. Our own researches have focussed on this point. We show that outbreaks of serious respiratory disease, local in nature but causing unusual patterns of mortality, were indeed reported by scientists and doctors in army hospitals in England and in France, well before the first wave of the pandemic had arrived. We use the records of these hospitals, now held in the National Archives, to trace the progress of this disease amongst the individuals who fell ill. We examine contemporary reactions to this minor epidemic – an epidemic, we suggest, which acted as a herald wave of the pandemic yet to come. The latter part of our paper addresses the second question, as to how troop movement across the North Atlantic, once the United States had entered into war, may well have enabled the virus to spread from Europe to North America.

Source: 

Link: https://www.cambridge.org/core/journals/medical-history/article/spanish-influenza-pandemic-new-evidence-for-influenza-outbreaks-in-england-and-france-prior-to-1918/8BC01CCE54683ED7A4DD1DFF0C3AE7EA

____

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 19 '26)

 

Biochem Biophys Res Commun

1. CHEN M, Chen W, Jiang X, Liang S, et al
   Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline.
   Biochem Biophys Res Commun. 2026;814:153643.
   PubMed         Abstract available
   
   

   
   BMJ

2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
   Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
   BMJ. 2026;393:e087578.
   PubMed         Abstract available
   
   

   
   Drug Saf

3. HWANG CS, Lu Z, Russo M, Zakoul H, et al
   Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.
   Drug Saf. 2026;49:519-528.
   PubMed         Abstract available
   
   
4. COATES MM, Rowe SL, Sullivan SG, Munoz FM, et al
   Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.
   Drug Saf. 2026;49:567-580.
   PubMed         Abstract available
   
   
5. RACHWAL O, Gutierrez-Lobon M, Cueto NS, Ventura AN, et al
   Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases.
   Drug Saf. 2026;49:581-590.
   PubMed         Abstract available
   
   
6. JAJOU R, van Puijenbroek E, Overbeek J, Hek K, et al
   GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.
   Drug Saf. 2026;49:529-539.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

7. GONZALES BE, Ochoa TJ, van der Sande MAB
   Inequalities in complete pneumococcal vaccination among Peruvian children before and after the COVID-19 pandemic: An evaluation using demographic and health surveys from 2018 to 2023.
   Epidemiol Infect. 2026;154:e49.
   PubMed         Abstract available
   
   
8. KIMURA M, Asai Y, Tsuzuki S, Shimizu Y, et al
   Effectiveness of voluntary PCR testing against COVID-19 spread in remote Japanese islands.
   Epidemiol Infect. 2026;154:e48.
   PubMed         Abstract available
   
   

   
   J Virol Methods

9. ASGHARI M, Golalipour M, Memarian A, Farazmandfar T, et al
   Presentation of multiple copies of a non-dominant surface epitope by circular RNA effectively induce an immune response against SARS-CoV-2.
   J Virol Methods. 2026;343:115378.
   PubMed         Abstract available
   
   
10. CHIBA S
    Therapeutic mechanisms of early oseltamivir administration in the management of mild COVID-19 through the sympathetic nervous system: A scoping review.
    J Virol Methods. 2026;343:115386.
    PubMed         Abstract available
    
    

    
    Lancet

11. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    PubMed        
    
    
12. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    PubMed        
    
    

    
    PLoS Biol

13. SOLA I, Zuniga S
    New transcription signals in SARS-CoV-2 reshape virus-host interactions.
    PLoS Biol. 2026;24:e3003744.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

14. JEONG YD, Hart WS, Ishikane M, Kim KS, et al
    Identifying the optimal rapid antigen test for screening and determining the end of isolation: A modeling study.
    PLoS Comput Biol. 2026;22:e1013102.
    PubMed         Abstract available
    
    
15. ANOKYE F, Li MWZ, Walker S, Hurford A, et al
    Quantifying SARS-CoV-2 Omicron variant spread and the impact of non-pharmaceutical interventions in Newfoundland and Labrador, Canada.
    PLoS Comput Biol. 2026;22:e1013562.
    PubMed         Abstract available
    
    

    
    PLoS One

16. ABDELGHANY M, Yu F, Rennard S, Gwon Y, et al
    Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.
    PLoS One. 2026;21:e0346878.
    PubMed         Abstract available
    
    
17. BERBER E, Hanley HB, Gamez BM, Ross TM, et al
    Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022-2023, 2023-2024, and 2024-2025 seasons.
    PLoS One. 2026;21:e0347314.
    PubMed         Abstract available
    
    
18. MURALIDHAR K, Ngaybe MGB, Pope B, Nanjaiah S, et al
    Behavioural and Social Drivers (BeSD) of COVID-19 vaccination for children: A cross-sectional study of parental vaccine confidence and intent in Mysore, India.
    PLoS One. 2026;21:e0316877.
    PubMed         Abstract available
    
    
19. BHUPATHI M, Hegde S, Molloy JC, Devarapu GCR, et al
    MobileLAMP: A low-cost, portable incubation device for isothermal nucleic acid amplification.
    PLoS One. 2026;21:e0346874.
    PubMed         Abstract available
    
    
20. SHIMAZU Y, Isoda N, Hiono T, Hew YL, et al
    Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model.
    PLoS One. 2026;21:e0347205.
    PubMed         Abstract available
    
    
21. GANGAT R, Ngah V, Tawonga R, Blanford JI, et al
    Spatial and temporal patterns of SARS-CoV-2 infection in uMgungundlovu, KwaZulu-Natal, South Africa.
    PLoS One. 2026;21:e0317648.
    PubMed         Abstract available
    
    
22. VAN DUINKERKEN A, van der Velden PG, Duckers MLA, Baliatsas C, et al
    Revisiting the exposure criterion for PTSD: Using the COVID-19 pandemic as an opportunity to assess measurement invariance of PTSD symptoms across event types.
    PLoS One. 2026;21:e0347315.
    PubMed         Abstract available
    
    
23. KITTUR ME, Jones BDM, Imran S, Wang W, et al
    Impact of the COVID-19 pandemic on adults accessing specialist psychiatric care: A cross-sectional Canadian analysis.
    PLoS One. 2026;21:e0346913.
    PubMed         Abstract available
    
    
24. CASJENS S, Hovanec J, Glaser N, Massag J, et al
    Occupational risk factors for depression and anxiety symptoms: Insights from a large cohort study during and after the SARS-CoV-2 pandemic.
    PLoS One. 2026;21:e0346871.
    PubMed         Abstract available
    
    
25. JIANG KP, Bennett S, Yager P
    Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.
    PLoS One. 2026;21:e0344750.
    PubMed         Abstract available
    
    
26. ABBAS U, Laghari RN, Ahmed I, Musawwir UA, et al
    Acute SARS-CoV-2 viral load and systemic inflammation are associated with neuropsychiatric and musculoskeletal symptoms in long COVID.
    PLoS One. 2026;21:e0346978.
    PubMed         Abstract available
    
    
27. OZATO N, Hori S, Miyai N, Takase H, et al
    Association of visceral fat and plasmacytoid dendritic cell-derived interferon alpha with SARS-CoV-2 infection.
    PLoS One. 2026;21:e0344870.
    PubMed         Abstract available
    
    
28. DIAS GF, Fan C, Han M, Wang X, et al
    COVID-19 in hemodialysis patients: New insights into metabolomic profile dynamics from 60 days pre- to 60 days post-diagnosis.
    PLoS One. 2026;21:e0346687.
    PubMed         Abstract available
    
    
29. MOHTASHAM F, Hashemi Nazari SS, Pourhoseingholi MA, Kavousi K, et al
    Hybrid feature-selection and diversity-guided stacking framework for interpretable ensemble learning: Application to COVID-19 mortality prediction.
    PLoS One. 2026;21:e0341198.
    PubMed         Abstract available
    
    
30. LEE SJ, Kim J, Han M, Lee JA, et al
    Distinct plasma cytokine and chemokine profiles in severe COVID-19 and septic shock.
    PLoS One. 2026;21:e0347126.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

31. GOLDMAN N, Pebley AR
    The Latino health experience: Past and future.
    Proc Natl Acad Sci U S A. 2026;123:e2530795123.
    PubMed         Abstract available
    
    
32. HUOT M, Wang D, Shakhnovich E, Monasson R, et al
    Constrained evolutionary funnels shape viral immune escape.
    Proc Natl Acad Sci U S A. 2026;123:e2536956123.
    PubMed         Abstract available
    
    
33. FARIAS A, Bridgeman VL, Rodrigues FS, Puttur F, et al
    Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
    Proc Natl Acad Sci U S A. 2026;123:e2412919123.
    PubMed         Abstract available
    
    

    
    Vaccine

34. HSIEH SM, Choi MJ, Chen YC, Cheng SY, et al
    Cost-effectiveness of vaccination of older adults with an MF59(R)-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan.
    Vaccine. 2026;80:128533.
    PubMed         Abstract available
    
    
35. ANYALECHI EG, Marquez PL, Rubin MN, Johannsen SP, et al
    Safety of seasonal inactivated influenza vaccines in children 6 months-17 years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018-2023: before, during, and after the COVID-19 pandemic public health emergency.
    Vaccine. 2026;81:128569.
    PubMed         Abstract available
    
    

    
    Virology

36. SWIERKOT J, Tyczynska KM, Siemaszko J, Madej M, et al
    The association of selected genetic polymorphisms with adverse events following COVID-19 vaccination: a single-centre prospective observational cohort study.
    Virology. 2026;619:110876.
    PubMed         Abstract available
    
    
37. CHEN G, Liang D, Liu M, Lv Z, et al
    Theaflavins suppresses RSV infection by modulating the MAVS-I-IFN pathway.
    Virology. 2026;619:110872.
    PubMed         Abstract available
    
    
38. LIU R, Patterson L, Yeasmin M, Kim KH, et al
    Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.
    Virology. 2026;619:110884.
    PubMed         Abstract available
    
    
39. WANG Z, Wongnak R, Oba M, Mizutani T, et al
    Omicron RBD expressed in E. coli outperforms mammalian-expressed S1 spike protein in generating highly neutralizing anti-SARS-CoV-2 antibodies in mice.
    Virology. 2026;619:110894.
    PubMed         Abstract available
    
    
40. RICHARDSON SAS, Boodhoo N, Bhat S, Wells J, et al
    Differential outcomes of viral co-infections with high pathogenicity avian influenza A(H5N6) and SARS-CoV-2 in mammalian in vitro systems.
    Virology. 2026;620:110912.
    PubMed         Abstract available
    

Historical #Pandemic and Contemporary #Influenza A Viruses Reveal #PB2 M631L as a Convergent #Adaptation to #Human ANP32

 

Abstract

Understanding the genetic changes that allow avian influenza A viruses (IAVs) to switch their natural hosts and establish productive infection in humans is important for pandemic risk assessment. Adaptations in the IAV polymerase are required to overcome species-specific restrictions imposed by host ANP32 proteins. Notably, avian virus polymerase is generally only poorly supported by human ANP32 proteins due to species-specific differences. Consequently, efficient polymerase adaptation to the binding interface of human ANP32 requires distinct amino acid changes, such as PB2 E627K. A separate adaptation, PB2 M631L, has recently been reported in mammalian-adapted IAV; however, its functional role across divergent viral lineages and its relationship to host ANP32-dependent adaptation remain incompletely defined. Here, we examine PB2 M631L in the polymerases of a 1918 pandemic strain, a recombinant contemporary H1N1pdm09, and a recent clade 2.3.4.4b H5N1 virus. Using polymerase activity and protein-interaction assays, we show that PB2 M631L enhances polymerase activity and ANP32 binding in human—but not avian—contexts, and that this effect is conserved across multiple viral backgrounds. In H1N1pdm09, PB2 M631L also increased virus replication in mammalian cells. These findings indicate that PB2 M631L contributes to enhanced polymerase compatibility with human ANP32 proteins and are consistent with a role in adaptation across multiple influenza virus lineages. Our results highlight how analysis of historical pandemic strains can inform risk assessment for future emerging viruses.

Source: 

Link: https://www.mdpi.com/2076-2607/14/4/859

____

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 11 '26)

 

Biochemistry

1. VOGET R, Gutschow M
   Early Kinetic Characterization of SARS-CoV-2 Main Protease Inhibitors: A Review and Guidance for Biochemical Assessments.
   Biochemistry. 2026;65:860-881.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

2. MILLER AC, Boonstra DE, Cavanaugh JE, Boikos C, et al
   Disease burden associated with influenza activity at the population level.
   Epidemiol Infect. 2026 Apr 6:1-28. doi: 10.1017/S0950268826101320.
   PubMed        
   
   
3. ABUNIJELA S, Greiner T, Haas W, Kerber R, et al
   Frequency, dynamics, and duration of faecal shedding in SARS-CoV-2-infected individuals, a scoping review.
   Epidemiol Infect. 2026;154:e44.
   PubMed         Abstract available
   
   

   
   J Exp Med

4. MATHEW NR, Gailleton R, Scharf L, Schon K, et al
   Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza.
   J Exp Med. 2026;223:e20251793.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. ULANOWICZ CJ, Alarcon PC, Damen MSMA, Wayland JL, et al
   Distinct inflammatory programming of thoracic cavity white adipose immune cells regulates influenza pathogenesis.
   J Infect Dis. 2026 Apr 7:jiag201. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   N Engl J Med

6. PARDO-SECO J, Martinon-Torres F
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults. Reply.
   N Engl J Med. 2026;394:1454.
   PubMed        
   
   
7. JOHANSEN ND, Biering-Sorensen T
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults. Reply.
   N Engl J Med. 2026;394:1454.
   PubMed        
   
   
8. KANEDA Y, Fujikawa T
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults.
   N Engl J Med. 2026;394:1453-1454.
   PubMed        
   
   
9. CHEN HY, Liao JC, Yong SB
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults.
   N Engl J Med. 2026;394:1453.
   PubMed        
   
   

   
   Pediatrics

10. OLSON SM, Ahmad HM, Wielgosz K, Michaels MG, et al
    Pediatric Vaccine Effectiveness Against Influenza Hospitalization And Outpatient Visits: 2021-2024.
    Pediatrics. 2026 Apr 6:e2025073973. doi: 10.1542/peds.2025-073973.
    PubMed         Abstract available
    
    
11. LUCACCIONI H, Maurel M, Perez-Gimeno G, Buda S, et al
    Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022-2024.
    Pediatrics. 2026 Apr 6:e2025072907. doi: 10.1542/peds.2025-072907.
    PubMed         Abstract available
    
    

    
    PLoS One

12. ANTAO V, Krueger P, Meaney C, Kwong JC, et al
    Predictors of burnout among academic family medicine faculty: Looking back to plan forward.
    PLoS One. 2026;21:e0344702.
    PubMed         Abstract available
    
    
13. SPINOS D, Beech T, Lee J, Coulson C, et al
    Referral to treatment times in the National Health Service of England: A five-year analysis of the impact of the COVID-19 Pandemic and socioeconomic deprivation and future implications for Ear, Nose and Throat service delivery.
    PLoS One. 2026;21:e0346596.
    PubMed         Abstract available
    
    
14. SHARBAYTA SS, Jo Y, Jung J, Buonomo B, et al
    The impact of human behavioral adaptation stratified by immune status on COVID-19 spread with application to South Korea.
    PLoS One. 2026;21:e0345642.
    PubMed         Abstract available
    
    
15. GRAFF I, Berger M, Schmid M, Kogej M, et al
    A decade of triage with the Manchester Triage System-The MTS big data study.
    PLoS One. 2026;21:e0344598.
    PubMed         Abstract available
    
    
16. FELLER RL, Narraway CL, Burslem DF, Colucci-Gray L, et al
    Private garden uses and associated mental well-being benefits during the first UK Covid-19 lockdown - a social media investigation.
    PLoS One. 2026;21:e0289446.
    PubMed         Abstract available
    
    
17. PAN C, Shen W
    Revisiting price linkages between London and Shanghai base metal futures markets: A time-frequency connectedness analysis.
    PLoS One. 2026;21:e0346602.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. HA J, Sharma P, Ta S, Tsukuda S, et al
    Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.
    Proc Natl Acad Sci U S A. 2026;123:e2506647123.
    PubMed         Abstract available
    
    
19. PARENTI NA, Cusic R, Renner DM, Jackson N, et al
    SARS-CoV-2 and MERS-CoV disrupt host protein synthesis via nsp1 with differential effects on the integrated stress response.
    Proc Natl Acad Sci U S A. 2026;123:e2536296123.
    PubMed         Abstract available
    
    

    
    Vaccine

20. MCCULLOUGH R, Reid A, Smyth D, O'Neill MT, et al
    Leadership matters: ward manager vaccination status influences nursing staff influenza vaccine uptake.
    Vaccine. 2026;80:128541.
    PubMed         Abstract available
    
    
21. ZHANG J, Gong C, Xu Z, Han R, et al
    Multi-mode spatial accessibility to vaccination services and its impact on influenza-related hospitalisations among older adults.
    Vaccine. 2026;80:128540.
    PubMed         Abstract available
    
    

    
    Virus Res

22. WU Y, Sun W, Xia Y, Feng Y, et al
    The influenza B virus candidate vaccine expressing H3 hemagglutinin developed in suspension MDCK cells confers protection against lethal H3N2 avian influenza in BALB/c mice.
    Virus Res. 2026;367:199722.
    PubMed         Abstract available
    

#Birth #imprinting effects on the #antibody responses of #H7N9 patients from 2013-2018 in #China

 

Abstract

Background

There is an urgent need to understand the immune correlates of protection against avian influenza viruses (AIV), where pre-existing immunity may be limited.

Methods

Here, we characterized the antibody response in 12 severely ill A(H7N9) patients and examined its association with early-life imprinting and clinical outcome.

Results

We find that A(H7N9) patients imprinted with A(H2N2) during early life show minimal H7-IgM and a rapid IgG response across diverse hemagglutinin subtypes. They also have more high avidity H7-antibodies compared to older or younger patients. Early antibody titers against seasonal H1, H3, and conserved stalk domains trend negatively with clinical severity in A(H7N9) infection, while an inverse pattern is observed following severe A(H1N1) infection, potentially suggesting a different mechanism of immune regulation between seasonal and avian influenza virus infections.

Conclusions

These data provide direct serological evidence that birth imprinting profoundly shapes the humoral immune landscape during zoonotic influenza infection and may influence subsequent disease outcome.

Source: 

Link: https://www.nature.com/articles/s43856-026-01554-1

____

Using an evolutionary epidemiological #model of #pandemics to estimate the #infection #fatality ratio for #humans infected with avian #influenza viruses

 

Abstract

The risk of highly pathogenic avian influenza virus infection to humans is challenging to estimate as many human avian influenza virus (AIV) infections are undetected because infections may be asymptomatic, symptomatic but not tested, and difficult to identify through contact tracing, as human-to-human transmission is rare. We derive equations that consider the evolutionary mechanisms that give rise to pandemics and are parameterized to be consistent with records of past pandemics. We estimate that thousands of human AIV infections occur worldwide in an average year and estimate the infection fatality ratio as 32 deaths per 10,000 infections (95% confidence interval: [9.6, 75]). This estimate is comparable to SARS-CoV-2 during the recent pandemic and higher than seasonal human influenza. We estimate that preventing animal-to-human influenza spillovers would delay pandemic emergence by several years. Preventing human infections with AIV is necessary given the high risk of severe outcomes to individuals and to reduce the risk of pandemics occurring in the future.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

AH was supported by a Natural Sciences and Engineering Research Council of Canada Discovery Grant (RGPIN 023-05905) and a Catalyst Grant: Avian Influenza OneHealth Research, Enhanced tracking of the circulation of and risk from highly pathogenic avian influenza viruses at the human-wildlife interface from the Canadian Institutes of Health Research. JM, ML, and AH were support by an Atlantic Canada Research in the Mathematical Sciences Collaborative Research Group award.

Source: 

Link: https://www.medrxiv.org/content/10.64898/2026.01.21.26344526v2

____

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 4 '26)

 

Antimicrob Agents Chemother

1. VETTER P, Cabecinhas ARG, Schibler M, Kaiser L, et al
   Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza.
   Antimicrob Agents Chemother. 2026 Mar 27:e0165925. doi: 10.1128/aac.01659.
   PubMed         Abstract available
   
   

   
   J Infect Dis

2. HUNT JH, Damhorst GL, Parsons R, Frediani JK, et al
   Peak Nasal SARS-CoV-2 and Influenza Viral Loads Relative to Symptom Onset, 2022-2025: Impact of Vaccination and Implications for Multiplexed Testing.
   J Infect Dis. 2026 Apr 1:jiag169. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

3. KIM K-H, Hwang HS, Pal SS, Tien Le CT, et al
   Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity.
   J Virol. 2026 Mar 27:e0022926. doi: 10.1128/jvi.00229.
   PubMed         Abstract available
   
   
4. CIACCI ZANELLA G, Cardenas MI, Hutter CR, Snyder CA, et al
   Impact of maternal antibodies and weaning stress on the replication and transmission of human H3N2 influenza A in piglets.
   J Virol. 2026 Mar 27:e0197525. doi: 10.1128/jvi.01975.
   PubMed         Abstract available
   
   

   
   MMWR Morb Mortal Wkly Rep

5. MEGHANI M, Garacci Z, Razzaghi H, de Perio MA, et al
   Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season.
   MMWR Morb Mortal Wkly Rep. 2026;75:164-171.
   PubMed         Abstract available
   
   

   
   PLoS Biol

6. MULLOY RP, Evseev D, Sharlin N, Bui-Marinos MP, et al
   Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses.
   PLoS Biol. 2026;24:e3003646.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

7. GANGWAR P, Katte P, Bhat M, Turakhia Y, et al
   WEPP: Phylogenetic placement achieves near-haplotype resolution in wastewater-based epidemiology.
   PLoS Comput Biol. 2026;22:e1014124.
   PubMed         Abstract available
   
   
8. ORSINELLI-RIVERS S, Beaglehole D, Einav T
   CAPYBARA: A generalizable framework for predicting serological measurements across human cohorts.
   PLoS Comput Biol. 2026;22:e1014129.
   PubMed         Abstract available
   
   

   
   PLoS Med

9. XIAO H, Bai G, Liu F, Cui Y, et al
   Policy stringency during the COVID-19 pandemic and healthcare services utilization in China: An interrupted time-series analysis.
   PLoS Med. 2026;23:e1004672.
   PubMed         Abstract available
   
   

   
   PLoS One

10. BRAUN J, Hill ED, Contreras E, Yasuda M, et al
    Contrasting effects of SARS-CoV-2 vaccination vs. infection on antibody and TCR repertoires.
    PLoS One. 2026;21:e0343939.
    PubMed         Abstract available
    
    
11. ADYNSKI GI, Dictus C, Adynski H, Killela MK, et al
    Experiences of registered nurses and nursing assistants during COVID-19: Work stress, stress appraisal, and workplace resources; A qualitative descriptive study.
    PLoS One. 2026;21:e0345525.
    PubMed         Abstract available
    
    
12. BORBOR-CORDOVA MJ, Searles M, Roa-Lopez H, Cornejo-Rodriguez MDP, et al
    Integrating psychosocial health into disaster risk management: Insights from COVID-19 in Duran, Ecuador.
    PLoS One. 2026;21:e0343239.
    PubMed         Abstract available
    
    
13. HASSAN M, Iqbal MS, Yasir M, Chun W, et al
    Assessment of miRNAs as transcriptional regulators in respiratory syncytial virus infection through computational analysis and molecular docking studies.
    PLoS One. 2026;21:e0345571.
    PubMed         Abstract available
    
    
14. NAKAZATO T, Romani-Romani F, Gutierrez C
    Screen time and chronic neck pain in Peru: A comparative population-based cross-sectional study in the COVID-19 post-pandemic period.
    PLoS One. 2026;21:e0344257.
    PubMed         Abstract available
    
    
15. PARK H, Miyano S
    Network-constrained Random Lasso for biologically interpretable gene network inference across unequal sample sizes.
    PLoS One. 2026;21:e0344198.
    PubMed         Abstract available
    
    
16. USAMA M, Azeem M, Mustafa G
    Computational prediction of binding affinity and structural impact of three Pakistani SARS-CoV-2 spike RBD variants on human ACE2 interaction.
    PLoS One. 2026;21:e0346242.
    PubMed         Abstract available
    
    
17. KIM SY, Kim G, Park S, Kim C, et al
    Voting intentions during the later stage of the COVID-19 pandemic: The roles of risk perception and performance evaluations in South Korea.
    PLoS One. 2026;21:e0345621.
    PubMed         Abstract available
    
    
18. CHUEMCHIT M, Linn N, Han CPP, Lynn Z, et al
    Violence against women migrant workers in Thailand: A cross-sectional study on experiences, impact, and help seeking.
    PLoS One. 2026;21:e0345790.
    PubMed         Abstract available
    
    
19. WONG KH, Pandya N, McCollum S, Shabanova V, et al
    Language barriers in pediatric food allergy care: A single-center study on healthcare disparities.
    PLoS One. 2026;21:e0346248.
    PubMed         Abstract available
    
    
20. VELTHUIJS ELM, Ismail I, de Leeuw RA, Hehenkamp WJK, et al
    Evaluating patient harm minimization during the COVID-19-driven reduction in benign gynecological care: a nationwide claims-based longitudinal study in the Netherlands.
    PLoS One. 2026;21:e0345619.
    PubMed         Abstract available
    
    
21. RODRIGUEZ LIMA DR, Molano-Gonzalez N, Vargas Villanueva A, Pinilla Rojas DI, et al
    Mechanical ventilation as an independent risk factor for mortality in COVID-19-related ARDS: A secondary analysis using propensity score weighting.
    PLoS One. 2026;21:e0344866.
    PubMed         Abstract available
    
    
22. LESTARI BW, Alifia A, Karnawati PWW, Ramadhani NS, et al
    Assessment of post-pandemic NAAT-based diagnostic capacity among laboratories with COVID-19 testing resource investments in Indonesia.
    PLoS One. 2026;21:e0343628.
    PubMed         Abstract available
    
    
23. BECK WELLS M
    Disciplinary removal patterns among students with other health impairments and emotional disturbance: A three-year descriptive analysis of IDEA Part B data.
    PLoS One. 2026;21:e0346338.
    PubMed         Abstract available
    
    
24. HASEEB MW, Toutounji M
    Non-markovian electron tunneling in SARS-CoV-2 virus infection in structured environments.
    PLoS One. 2026;21:e0344447.
    PubMed         Abstract available
    
    
25. IUNES FM, Aranha Rossi T, Soares F, Torres TS, et al
    Factors associated with COVID-19 vaccination schedule completion among adults in high-social-vulnerability neighborhoods in two Brazilian state capitals: A cross-sectional study.
    PLoS One. 2026;21:e0346091.
    PubMed         Abstract available
    
    
26. RIBEIRO NM, Alexandre d'Auria de Lima MCR, Monroe AA, Vinci ALT, et al
    Health and social policies to advance Brazil's End TB agenda during and after COVID-19: An analysis from tripartite governance and normative innovation perspectives.
    PLoS One. 2026;21:e0345867.
    PubMed         Abstract available
    
    
27. STANDEN C, Tordjmann E, Wood J, Haigh F, et al
    Associations between area-level socioeconomic disadvantage and COVID-19 disease consequences in Sydney, Australia: A retrospective cohort analysis.
    PLoS One. 2026;21:e0334206.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. CORELL-ESCUIN P, Belmonte-Ballester S, Adhav A, Marina A, et al
    Dermcidin has antiviral activity and protects against influenza.
    Proc Natl Acad Sci U S A. 2026;123:e2424461123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. CHAN CP, Wong NS, Lee SS
    Normalising enhanced influenza vaccines as a strategy to promote vaccination uptake in healthcare workers: Insights from a discrete choice experiment.
    Vaccine. 2026;80:128539.
    PubMed         Abstract available
    
    
30. PODER A, Trinidad-Aseron M, Van Twuijver E, Versage E, et al
    Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study.
    Vaccine. 2026;80:128504.
    PubMed         Abstract available
    
    
31. TSCHERNE A, Krammer F
    Seven decades after the Asian influenza pandemic: A historical review about immunity and vaccines against H2N2.
    Vaccine. 2026;79:128467.
    PubMed         Abstract available
    
    
32. VAN TRUONG L, Van Nguyen T, Trang VTT, Le TTT, et al
    Determinants of COVID-19 vaccine hesitancy across 186 countries: a multifaceted analysis using structural equation modeling.
    Vaccine. 2026;78:128196.
    PubMed         Abstract available
    
    
33. PHIJFFER EWEM, Sivakumar C, van den Hoogen A, Crombag NMTH, et al
    Preferences of Dutch pregnant women for RSV immunisation - a mixed method study.
    Vaccine. 2026;78:128409.
    PubMed         Abstract available
    
    
34. WANG X, Patel C, Sharma K, Giles ML, et al
    Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies.
    Vaccine. 2026;78:128399.
    PubMed         Abstract available
    
    
35. RUIZ-PALACIOS GM, Cahn PE, Halperin SA, Wang R, et al
    Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.
    Vaccine. 2026;78:128378.
    PubMed         Abstract available
    
    
36. LYONS AJ, Mhatre MM, Argenio K, Day S, et al
    Does human papillomavirus vaccination status differ by disability status in New York city public schools?
    Vaccine. 2026;78:128404.
    PubMed         Abstract available
    
    
37. SABATE M, Riera-Arnau J, Ballarin E, Pares-Badell O, et al
    Validation of Guillain-Barre syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria.
    Vaccine. 2026;78:128397.
    PubMed         Abstract available
    
    

    
    Virology

38. RAMUTH M, Sonoo J, Pyndiah N, Rughooputh S, et al
    Epidemiology of influenza A and B viruses in Mauritius over an 8-year period, 2009-2016.
    Virology. 2026;619:110892.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, March 28 '26)

 

Antimicrob Agents Chemother

1. ZHOU J, Yan S, Zhao Y, Zhang H, et al
   A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza.
   Antimicrob Agents Chemother. 2026 Mar 23:e0166825. doi: 10.1128/aac.01668.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. KIM S, Kim JW, Ayoobi A, Lee S, et al
   A plant gallotannin pentagalloyl d-glucose elicits antiviral activity against influenza A and B viruses through multi-targeting mechanisms.
   Arch Virol. 2026;171:139.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

3. JACKSON C, Wijlaars L, Abdullahi F, Liu M, et al
   Paediatric infection hospital admissions in England before, during, and after the COVID-19 pandemic.
   Epidemiol Infect. 2026;154:e33.
   PubMed         Abstract available
   
   
4. TADA A, Otake S, Kusano T, Hoshino T, et al
   Clinical features and trends of severe paediatric group A streptococcal infections in Japan in the post-COVID-19 pandemic era.
   Epidemiol Infect. 2026;154:e35.
   PubMed         Abstract available
   
   

   
   J Gen Virol

5. CHIU HP, Yeo YY, Lai TY, Hung CT, et al
   SARS-CoV-2 Nsp15 facilitates immune evasion and viral replication by limiting multiple host innate immune pathways, including cGAS-STING.
   J Gen Virol. 2026;107.
   PubMed         Abstract available
   
   
6. AMARBAYASGALAN S, Takahashi T, Sugiura Y, Shimizu K, et al
   Bovine respiratory syncytial virus utilizes the human insulin-like growth factor 1 receptor in the late stages of infection.
   J Gen Virol. 2026;107.
   PubMed         Abstract available
   
   

   
   J Infect

7. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia.
   J Infect. 2026;92:106727.
   PubMed         Abstract available
   
   
8. ZHANG H, Kang Z, Zhang Y, Yang Y, et al
   Evolutionary dynamics and global spread of macrolide-resistant Bordetella pertussis during the post-pandemic pertussis resurgence.
   J Infect. 2026 Mar 7:106718. doi: 10.1016/j.jinf.2026.106718.
   PubMed         Abstract available
   
   

   
   J Virol

9. BUTH SA, Marin M, Zhang Y, Avinoam O, et al
   Cyclosporine A rescues the influenza virus fusion with IFITM3-expressing cells by relocating the restriction factor to intraluminal vesicles of multivesicular bodies.
   J Virol. 2026 Mar 25:e0204525. doi: 10.1128/jvi.02045.
   PubMed         Abstract available
   
   
10. KURYSHKO M, Luttermann C, Bayoumi M, Mostafa A, et al
    Host-specific functional evolution of seal influenza A virus NS1 protein following avian-to-seal transmission.
    J Virol. 2026 Mar 24:e0165025. doi: 10.1128/jvi.01650.
    PubMed         Abstract available
    
    
11. LI S, Liu DX
    Interaction of coronavirus E protein with BRD2 plays important regulatory roles in viral replication and induction of pro-inflammatory response.
    J Virol. 2026 Mar 3:e0220125. doi: 10.1128/jvi.02201.
    PubMed         Abstract available
    
    
12. NOORUZZAMAN M, Butt SL, Rani R, Ye C, et al
    The ORF6 accessory protein contributes to SARS-CoV-2 virulence and pathogenicity in the naturally susceptible feline model of infection.
    J Virol. 2026 Feb 27:e0064425. doi: 10.1128/jvi.00644.
    PubMed         Abstract available
    
    
13. LIN S, Chen X, Luo M, Cui X, et al
    DIDS modulates VDAC1 oligomerization to suppress intrinsic apoptosis and attenuates in vitro and in vivo RSV infection.
    J Virol. 2026;100:e0220025.
    PubMed         Abstract available
    
    
14. YAO Q, Mahase V, Hou W, Cruz-Cosme R, et al
    Computational and experimental identification of potential neutralizing peptides derived from human ACE2 against SARS-CoV-2 infection.
    J Virol. 2026 Jan 30:e0146825. doi: 10.1128/jvi.01468.
    PubMed         Abstract available
    
    

    
    Lancet

15. JERNIGAN DB, Rivers CM
    Learning from swine influenza, Ebola virus disease, and Legionnaires' disease in 1976.
    Lancet. 2026 Mar 19:S0140-6736(26)00460-5. doi: 10.1016/S0140-6736(26)00460.
    PubMed        
    
    

    
    PLoS One

16. MA X
    Optimizing online teaching effectiveness in elementary education: Exploring multifaceted pathways based fsQCA analysis.
    PLoS One. 2026;21:e0345463.
    PubMed         Abstract available
    
    
17. ATAYA F, Alamro A, Alghamdi A, Fouad D, et al
    Identification of polyphenols as novel neuropilin-1 cendR pocket inhibitors to block SARS-CoV-2 entry and enhance variant resistance.
    PLoS One. 2026;21:e0345051.
    PubMed         Abstract available
    
    
18. MIKI M, Shimazu Y, Obara RD, Nagamine T, et al
    Assessment of a baloxavir marboxil treatment protocol for high pathogenicity avian influenza in Okinawa Rails, an endangered species endemic to Japan.
    PLoS One. 2026;21:e0345055.
    PubMed         Abstract available
    
    
19. MATTHYS A, Amelinck L, Smet A, Ysenbaert T, et al
    Internal gene segments from a mouse-adapted influenza B virus confer increased pathogenicity to mice.
    PLoS One. 2026;21:e0335324.
    PubMed         Abstract available
    
    
20. WANG L, Xia Y, Goh EH, Chen M, et al
    A smoothing and bootstrap-based framework for early outbreak detection.
    PLoS One. 2026;21:e0345088.
    PubMed         Abstract available
    
    
21. NUNES BP, Crochemore-Silva I, Mielke GI, Vidaletti LP, et al
    Social inequalities in the misbelief of chloroquine's protective effect against COVID-19: results from the EPICOVID-19 study in Brazil.
    PLoS One. 2026;21:e0341666.
    PubMed         Abstract available
    
    
22. FREITAS NL, Oliveira RD, Santos AKDS, Cunha-Filho M, et al
    Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients.
    PLoS One. 2026;21:e0345280.
    PubMed         Abstract available
    
    
23. CORONADO GD, Dickerson JF, Tsou MH, Shivaprakash N, et al
    Temporal and geographic analyses of colorectal cancer screening during and after the COVID-19 pandemic in a federally qualified health center.
    PLoS One. 2026;21:e0345248.
    PubMed         Abstract available
    
    
24. SUN X, Cappelleri JC, Lupton LL, Moran MM, et al
    Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy.
    PLoS One. 2026;21:e0345639.
    PubMed         Abstract available
    
    
25. CALANCIE L, Pan Y, Bassarab K, Stowers KC, et al
    Association between local food policy council coverage and longitudinal household food insufficiency during COVID-19, stratified by race, ethnicity, and income.
    PLoS One. 2026;21:e0345654.
    PubMed         Abstract available
    
    
26. DAGHER M, Abboud A, Saad GE, Itani R, et al
    Predictors of employment attrition in Lebanon during multifaceted crises: The role of chronic diseases - a national cross-sectional study.
    PLoS One. 2026;21:e0328028.
    PubMed         Abstract available
    
    
27. KAWABATA J, Goto K, Maeda M, Fukuda H, et al
    Comparison of post-discharge mortality and medical expenditures in COVID-19 patients according to mechanical ventilation and extracorporeal membrane oxygenation use: The LIFE study.
    PLoS One. 2026;21:e0345939.
    PubMed         Abstract available
    
    
28. SIRAPHATWONGKORN A, Methiyothin T, Onuean K, Chinnasarn K, et al
    Forecasting Thailand's mobility trends using Feature Engineered XGBoost for pandemic crisis movement management.
    PLoS One. 2026;21:e0345547.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

29. SMITH E, Blaabaek EH, Reimer D, Jaeger MM, et al
    Gender gaps in reading increase during unplanned and planned school closures.
    Proc Natl Acad Sci U S A. 2026;123:e2523152123.
    PubMed         Abstract available
    
    
30. BATRA H, Luo S, Saunders KO, Higgins JS, et al
    Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V(H)1-2-rearranging mouse models.
    Proc Natl Acad Sci U S A. 2026;123:e2537053123.
    PubMed         Abstract available
    
    
31. VRIENDS MBL, Moran E, Calvelo M, Hansen T, et al
    Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents.
    Proc Natl Acad Sci U S A. 2026;123:e2504045123.
    PubMed         Abstract available
    
    
32. BALAKRISHNAN K, Chakraborty S, Chiang C, Stratton CM, et al
    Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation.
    Proc Natl Acad Sci U S A. 2026;123:e2528398123.
    PubMed         Abstract available
    
    
33. KADAM RU, Juraszek J, Brandenburg B, Garg D, et al
    Small molecule-constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins.
    Proc Natl Acad Sci U S A. 2026;123:e2537533123.
    PubMed         Abstract available
    
    
34. HARIT A, Mor M, Yefet R, Izhaki-Tavor LS, et al
    Monoclonal antibodies from COVID-19 convalescent patients target cryptic epitopes for broad SARS-CoV-2 neutralization.
    Proc Natl Acad Sci U S A. 2026;123:e2523864123.
    PubMed         Abstract available
    
    
35. VENTURA PC, Dam Jeong Y, Litvinova M, Kummer AG, et al
    VIBES: A multiscale modeling approach integrating within-host and between-hosts dynamics in epidemics.
    Proc Natl Acad Sci U S A. 2026;123:e2523055123.
    PubMed         Abstract available
    
    

    
    Vaccine

36. FRAWLEY JE, Hutchens J, Wiley K, Mahimbo A, et al
    Uptake of Commonwealth funded influenza vaccines for Australian children aged 6-months to <5 years during the COVID-19 pandemic.
    Vaccine. 2026;79:128514.
    PubMed         Abstract available
    
    

    
    Virus Res

37. FERREIRO I, Hurtado J, Bruno A, Cristina J, et al
    On the brink of emergence: an evolutionary approach to Influenza A virus H5N1 isolated from humans.
    Virus Res. 2026 Mar 21:199717. doi: 10.1016/j.virusres.2026.199717.
    PubMed         Abstract available